Respiratory syncytial virus rsv - Open Access .click

Results 161 to 170 of about 1,747,273 (202)

Some of the next articles are maybe not open access.

Perspectives for the chemotherapy of respiratory syncytial virus (RSV) infections

International Journal of Antimicrobial Agents, 1996
Respiratory syncytial virus (RSV) is the major respiratory pathogen in infants and young children. Ribavirin is the only antiviral agent approved for the treatment of RSV infections, but its efficacy has remained controversial. In the past few years several compounds have been described that in vitro exhibit marked activity against RSV at a 50 ...
openaire +2 more sources

Forward and reverse translational approaches to predict efficacy of neutralizing respiratory syncytial virus (RSV) antibody prophylaxis

EBioMedicine, 2021
Li Qin, Jeffrey R Sachs, Kalpit A Vora
exaly

Breakthrough therapy designation of nirsevimab for the prevention of lower respiratory tract illness caused by respiratory syncytial virus infections (RSV)

Expert Opinion on Investigational Drugs, 2022
Harrison Bergeron, Ralph A. Tripp
exaly

Parental knowledge about respiratory syncytial virus (RSV) and attitudes to infant immunization with monoclonal antibodies

Expert Review of Vaccines, 2022
Gitte Lee Mortensen
exaly

Development of mRNA vaccines against respiratory syncytial virus (RSV)

Cytokine and Growth Factor Reviews, 2022
Ji Jianjian, Yangtian Yan
exaly

Respiratory Syncytial Virus (RSV)

2019
openaire +2 more sources

Unnecessary antibiotic treatment of children hospitalised with respiratory syncytial virus (RSV) bronchiolitis: risk factors and prescription patterns

Journal of Global Antimicrobial Resistance, 2021
Uri Obolski, Eias Kassem, Khitam Muhsen
exaly